Sri Siddhartha Academy of Higher Education



COVID -19: BULLETIN: - 7

10-06-2020

Under the **Guidance** of Honourable Vice Chancellor Dr. P. Balakrishna Shetty Sri Siddhartha Academy of Higher Education has prepared COVID-19 Bulletin.

Prepared by:

- 1. Dr. Sudeep Kumar M, Deputy Registrar, SSAHE
- 2. Dr. Girish Babu R.J, HOD Microbiology, SSIMS&RC
- 3. Dr. Narayana K, HOD Pharmacology, SSIMS&RC
- 4. Dr. Keerthi H, Dept of Psychiatry, SSIMS&RC
- 5. Dr. Ramya K.S, Dept of Community Medicine, SSIMS&RC

POLITICAL SCENARIO

USA

- India and China will have more cases with more tests: Trump.
- US to allow limited flights by Chinese airlines.

SPAIN

- Spain extends corona virus lockdown until June 21.
- Spain aims to reopen borders in June as COVID-19 death fall again.

ITALY

- Italy leads Europe in reopening of borders.
- PM Giuseppe Conte offered a hopeful message as the country moved to its final stage in easing lockdown restrictions.

FRANCE

- Paris returns to cafe life with new normal.
- The COVID-19 epidemic is retreating in mainland France with four key indicators suggesting that it is under control.

GERMANY

- Germany moves to reactivate European travel as corona virus ebbs.
- Germany gets ready to launch corona virus training application.

UK

- UK watchdog to probe virus racial inequalities.
- UK daily death drop to pre lockdown level.

RUSSIA

- Russia to partly reopen borders after easing COVID-19 restrictions.
- Russia plans to resume international air travel on July 15, Domestic airlines flights June 17.

BRAZIL

- Brazil threatens to quit WHO over ideological basis
- Brazil yanks COVID-19 death toll as data befuddles experts

PERU

- Peruvian President Martin Vizcarra signed a supreme decree extending Peru is Health State of Emergency for 90 days.
- At least 20 journalists died from COVID-19 as they covered pandemic.

INDIA

- Don't drop your guard: PM Modi ahead of unlock 1.0.
- India: Case fatality rate among lowest in the world.
- PM preaches self reliance to India Inc.
- Karnataka: Experts say no to institutional quarantine.
- Centre rolls out rules for opening hotels, temples.
- Amid pandemic shadow centre not to float new schemes.
- India adding cases faster despite 48% recoveries.


EPIDEMIOLOGY SCENARIO

Total confirmed COVID-19 cases




The number of confirmed cases is lower than the number of total cases. The main reason for this is limited testing.





Source: European CDC - Situation Update Worldwide - Last updated 10th June, 12:00 (London time) OurWorldInData.org/coronavirus • CC BY



COVID-19 Tracker

States/UT	Infected	Death
Maharashtra	90,787	3289
Tamil Nadu	34,914	307
Delhi	29,943	874
Gujarat	21,044	1313
Uttar Pradesh	11,335	301
Rajasthan	11,245	255
Madhya Pradesh	9,638	414
West Bengal	8,985	415
Karnataka	5,921	66
Bihar	5,455	33
Haryana	5,209	45
Andhra Pradesh	5,029	77
J&K	4,346	48
Telangana	3,920	148
Odisha	3,140	9
Assam	2,937	5

States/UT	Infected	Death
Punjab	2,719	55
Kerala	2,095	16
Uttarakhand	1,537	13
Jharkhand	1,416	8
Chhattisgarh	1,211	5
Tripura	841	0
Himachal Pradesh	438	6
Goa	359	0
Chandigarh	323	5
Manipur	304	0
Others	606	3
Unassigned	8,803	

1,33,024 TOTAL ACTIVE CASES

1,33,766 TOTAL RECOVERED 7,710
TOTAL DEATH
TOLL

2,74,500 TOTAL INFECTED

District-wise Covid-19 tally				
District	Positive	Discharged	Active	Deaths
Udupi	947	234	712	01
Kalaburagi	769	213	548	80
Yadgir	642	91	550	01
Bengaluru Urban	522	298	204	19
Raichur	359	82	276	01
Mandya	334	236	98	0
Belagavi	301	151	149	01
Bidar	279	. 132	141	06
Hassan	211	150	61	0
Davangere	211	157	48	06
Dakshina Kannada	210	85	118	06
Vijayapura	204	131	67	06
Chikkaballapur	152	109	40	03
Mysuru	99	94	05	0
Uttara Kannada	96	72	24	0
Bagalkot	94	82	11	01
Shivamogga	73	31	42	0
Ballari	68	43	24	01
Dharwad	66	39	27	0
Gadag	49	33	14	02
Chitradurga	40	23	17	0
Bengaluru Rural	36	11	24	01
Tumakuru	34	28	04	02
Kolar	30	18	12	0
Haveri	22	11	- 11	0
Chikkamagaluru	18	18	0	0
Koppal	12	04	08	0
Others .	43	29	13	01
ourier s			(2 non-Covid deat	
Total	5921	2605	3248	68

CLINICAL SCENARIO

Sympto	ms	Coronavirus* (COVID-19) Symptoms range from mild to severe	Cold Gradual onset of symptoms	Flu Abrupt onset of symptoms	Seasonal Allergies Abrupt onset of symptoms
	th of otoms	7-25 days	Less than 14 days	7-14 days	Several weeks
Coug	gh .	Common (usually dry)	Common (mild)	Common (usually dry)	Rare (usually dry unless it triggers asthma)
Shor of br	tness eath	Sometimes	No**	No**	No**
Snee	zing	No	Common	No	Common
Runr	ny or y nose	Rare	Common	Sometimes	Common
Sore	throat	Sometimes	Common	Sometimes	Sometimes (usually mild)
Feve	r	Common	Short fever period	Common	No
	ng tired weak	Sometimes	Sometimes	Common	Sometimes
Head	laches	Sometimes	Rare	Common	Sometimes (related to sinus pain)
	/ aches pains	Sometimes	Common	Common	No
Diarr	hea	Sometimes	No	Sometimes for children	No

*Information is still evolving. **Allergies, colds and flus can all trigger asthma, which can lead to shortness of breath.

COVID-19 is the only one associated with shortness of breath on its own. Sources: Asthma and Allergy Foundation of America,

World Health Organization, Centers for Disease Control and Prevention.

edited 3/27/20 • aafa.org/covid19

- Tamil Nadu government to cap treatment cost for Covid-19 in private hospitals.
- Kolkata; Eye & Dental clinics begin ops after state approval.
- Delhi: Ganga Ram, Moolchand to be made Covid-19 hospitals.
- "Touchless hospitality" is the future.
- Hyderabad: on a trial basis, 11 Covid-19 patients with mild symptoms home quarantined.
- Three Indian manufacturers to commercialize NASA developed ventilator.

LABORATORY SCENARIO

• Unique stream of virus infecting India.

Jun 1, 2020


Jun 2

Jun 3

- Clade A3i group of virus now consists of 41% of the pathogen circulating in India.
- The dominant stream is Clade A2a which comprises more than 50% of the streams.
- Scientists say Clade A3i mutates less than Clade A2a.
- Clade A2a seen around world, Clade A3i mostly in India.

Daily COVID-19 tests per thousand people

Our World in Data



Source: Official data collated by Our World in Data

OurWorldInData.org/coronavirus • CC BY

Note: Comparisons of testing data across countries are affected by differences in the way the data are reported. Daily data is interpolated for countries not reporting testing data on a daily basis. Details can be found at our Testing Dataset page.

Jun 6

Jun 7

Total COVID-19 tests per 1,000 people, Jun 9, 2020

Jun 4


The figures shown relate to the closest date for which we have data, with a maximum of 10 days' difference.

Jun 5



Jun 9, 2020

Jun 8



Source: Official sources collated by Our World in Data

OurWorldInData.org/coronavirus • CC BY Note: Comparisons of testing data across countries are affected by differences in the way the data are reported. Details can be found at our Testing Dataset page.

THERAPEUTIC SCENARIO

Vaccine Update

Singapore biotech firm to begin human trial:

A Singapore-based biotechnology firm will begin human clinical trials next week for a potential monoclonal antibody treatment for Covid-19 that could slow down the progression of the disease in patients, help them recover faster, and provide temporary protection against it. Tychan; a firm backed by state investor Temasek Holdings, said in a statement on Wednesday has received approval from Singapore's Health Sciences Authority (HSA) for the phase 1 clinical safety trial in healthy volunteers. The firm has developed TYO27, a monoclonal antibody that specifically targets SARS-CoV-2, the coronavirus that causes Covid-19.

Johnson & Johnson to begin human trials of COVID-19 vaccine in the second half of July: J&J's study will test the vaccine against a placebo and assess the shot's safety and immune response in 1,045 healthy people aged 18 to 55 years, as well as those 65 years and older. The trial will take place in the United States and Belgium.

Coronavirus (Covid-19) vaccine latest update: Imperial College promises low-cost access to vaccine; UK's Imperial College vaccine to enter phase 1 and 2 human clinical trials on June 15.

China's first jab by autumn: Coranavirus (Covis-19) Vaccine Latest update: China's first Covid-19 vaccine may be ready for use by autumn.

China's Inactivated COVID-19 Vaccine Protects Animals from Disease:

Researches said that the pilot-scale production of the vaccine candidate induces high levels of neutralizing antibody concentrations in mice, rats, guinea pigs, rabbits and non-human primates.

Panacea Biotec To Partner With US-Based Refana Inc for COVID-19 Vaccine:

The collaboration aims to make more than 500 million doses of the vaccine candidate, with over 40 million doses expected to be available early next year, Panacea said in a statement to stock exchanges.

Europe to Accelerate Trials of Gene-engineered Coronavirus Vaccines:

Sources they are part of a wider EU strategy aimed at securing enough doses of a possible vaccine for the bloc as it fears lagging behind the United States and China.

China's Inactivated COVID-19 Vaccine Protects Animals from Disease:

Researches said that the pilot-scale production of the vaccine candidate induces high levels of neutralizing antibody concentrations in mice, rats, guinea pigs, rabbits and non-human primates.

Corona vaccine being developed in India will likely begin to be tested in people in October,

K. VijayRaghavan, Principal Scientific Adviser to the government, said at a press briefing on Thursday. "A group is working on a vaccine on a flu backbone. Preclinical studies are likely to be completed by October after which it is likely to move on to human trials," he said, without disclosing the identity of the company or group.